



Subject: Radiofrequency Tumor Ablation of Thyroid

Revision date: 5/25

DESCRIPTION

Radiofrequency ablation (RFA) of a tumor involves the delivery of high frequency alternating current to induce thermal injury of target tissue. Electrodes are inserted directly into the affected area where alternating high frequency current is then emitted. As the current moves into the surrounding tissue, it results in frictional heating of the tissue. As the temperature becomes elevated beyond 60 degrees Celsius, cells around the electrode begin to die (coagulative necrosis). This procedure can be performed percutaneously or through an intraoperative approach with CT, MRI, or ultrasound guidance.

Thyroid nodules are present in up to 60% of patients. Most of these nodules are benign. Benign nodules can lead to hyperthyroidism and compressive symptoms, such as airway compression, difficulty swallowing, or discomfort with clothing. Observation of these nodules may include medications for hyperthyroidism, follow-up visits, and multiple ultrasounds. Patients may experience long-term effects from hyperthyroidism or medication side effects. Surgical intervention involves anesthesia risks, need for thyroid replacement, surgical complications, and cosmetic concerns (scarring).

Thyroid RFA is similar to RFA of other organs but utilizes a lower wattage and finer needles. The procedure is performed in the office setting. A local anesthetic is injected into the region surrounding the thyroid gland then the radiofrequency catheter is guided into the nodule and the nodule is ablated. The advantages of thyroid RFA include:

- Office-based setting
- No incision
- Less need for thyroid supplementation
- No general anesthesia
- Cost-effective

APPLICABILITY

This policy applies to all OSU Health Plan (OSUHP) benefit plans.

DEFINITIONS

Radiofrequency ablation is a minimally invasive technique that shrinks the size of tumors, nodules, or other growths in the body.

Thyroid nodule is an unusual lump (growth) of cells on your thyroid gland.

Cytologically is the study of the detailed structure of a tissue, as revealed by microscopic examination.

Metastasis is when cancer spreads from where it started to a distant part of the body.

POLICY

Refer to MCG ACG: A-0718 *Radiofrequency Tumor Ablation* for non-thyroid indications and metastatic or recurrent thyroid cancer.

OSU Health Plan considers radiofrequency tumor ablation medically necessary for the following indications:

- Cytologically benign thyroid nodules when one or more of the following criteria are met:
 - Thyroid nodule is causing hyperthyroidism; or
 - Thyroid nodule is increasing in size and is at least 2 cm in diameter
- Malignant thyroid tumor when the following are met:
 - T1 or T2
 - No lymph node metastasis
 - Covered person is not a surgical candidate due to medical comorbidities
- Thyroid tumors when the criteria in MCG A-0718 *Radiofrequency Tumor Ablation* are met.

PROCEDURES

OSU Health Plan will cover Radiofrequency Tumor Ablation of Thyroid according to the above guidelines.

PRIOR AUTHORIZATION

Prior authorization is required for Radiofrequency Tumor Ablation of Thyroid.

EXCLUSIONS

OSU Health Plan considers thyroid RFA experimental and investigational for the following indications:

- Cytologically benign thyroid nodules that are asymptomatic and stable in size
- Cytologically benign thyroid nodules that are less than 2 cm in diameter

CODES

Codes covered when the above criteria are met:

Code	Description
0673T	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance

REFERENCES

Aetna. (2022). Radiofrequency Tumor Ablation.

https://www.aetna.com/cpb/medical/data/400_499/0492.html

Baek, J.H., Lee, J.H., Sung, J.Y., Bae, J.I., Kim, K.T., Sim, J., Baek, S.M., Kim, Y.S., Shin, J.H., Park,

J.S., Kim, D.W., Kim, J.H., Kim, E.K., Jung, S.L., Na, D.G. (2012). Korean Society of Thyroid Radiology, Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: A multicenter study. *Radiology*, 262(1), 335-42.

<https://doi.org/10.1148/radiol.11110416>

Bernardi, S., Dobrinja, C., Fabris, B., Bazzocchi, G., Sabato, N., Ulcigrai, V., Giacca, M., Barro, E., De Manzini, N., & Stacul, F. (2014). Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. *International Journal of Endocrinology*, 934595.

<https://doi.org/10.1155/2014/934595>

Bo, X.W., Lu, F., Xu, H.X., Sun, L.P., & Zhang, K. (2020). Thermal ablation of benign thyroid nodules and papillary thyroid microcarcinoma. *Frontiers in Oncology*, 10(580431), 1-10.

<https://doi.org/10.3389/fonc.2020.580431>

- Che, Y., Jin, S., Shi, C., Wang, L., Zhang, X., Li, Y., & Baek, J.H. (2015). Treatment of Benign Thyroid Nodules: Comparison of Surgery with Radiofrequency Ablation. *American Journal of Neuroradiology*, 36(7), 1321–1325. <https://doi-org.proxy.lib.ohio-state.edu/10.3174/ajnr.A4276>
- Chen, F., Tian, G., Kong, D., Zhong, L., & Jiang, T. (2016). Radiofrequency ablation for treatment of benign thyroid nodules. *Medicine*, 95(34), e4659. <https://doi.org/10.1097/MD.0000000000004659>
- Chung, S.R., Suh, C.H., Baek, J.H., Park, H.S., Choi, Y.J., & Lee, J.H. (2017). Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: A systematic review and meta- analysis. *International Journal of Hyperthermia*, 33(8), 920-930.
- Deandrea, M., Trimboli, P., Garino, F., Mormile, A., Magliona, G., Ramunni, M.J., Giovanella, L., & Limone, P.P. (2019). Long-Term Efficacy of a Single Session of RFA for Benign Thyroid Nodules: A Longitudinal 5-Year Observational Study. *The Journal of Clinical Endocrinology and Metabolism*, 104(9), 3751–3756. <https://doi.org/10.1210/jc.2018-02808>
- Ding, M., Tang, X., Cui, D., et al. (2019). Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma. *Clin Radiol*, 74(9), 712–7.
- Fuller, C.W., Nguyen, S.A., Lohia, S., & Gillespie, M.B. (2014). Radiofrequency ablation for treatment of benign thyroid nodules: Systematic review. *The Laryngoscope*, 124(1), 346–353. <https://doi.org/10.1002/lary.24406>
- Ha, S.M., Sung, J.Y., Baek, J.H., et al. (2017). Radiofrequency ablation of small follicular neoplasms: Initial clinical outcomes. *Int J Hyperth*, 33(8), 931–7.
- Hamidi, O., Callstrom, M.R., Lee, R.A., Dean, D., Castro, M.R., Morris, J.C., & Stan, M.N. (2018).

Outcomes of Radiofrequency Ablation Therapy for Large Benign Thyroid Nodules: A Mayo Clinic Case Series. *Mayo Clinic proceedings*, 93(8), 1018–1025.

<https://doi.org/10.1016/j.mayocp.2017.12.011>

Haugen, B.R., Alexander, E.K., Bible, K.C., et al. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*, 26(1), 1–133.

Huh, J.Y., Baek, J.H., Choi, H., Kim, J.K., & Lee, J.H. (2012). Symptomatic benign thyroid nodules: Efficacy of additional radiofrequency ablation treatment session--prospective randomized study. *Radiology*, 263(3), 909–916. <https://doi.org/10.1148/radiol.12111300>

Jeong, S.Y., Baek, J.H., Choi, Y.J., et al. (2018). Radiofrequency ablation of primary thyroid carcinoma: Efficacy according to the types of thyroid carcinoma. *Int J Hyperth*, 34(5), 611–6.

Jin, H., Lin, W., Lu, L., & Cui, M. (2021). Conventional thyroidectomy vs thyroid thermal ablation on postoperative quality of life and satisfaction for patients with benign thyroid nodules. *European Journal of Endocrinology*, 184(1), 131–141. <https://doi.org/10.1530/EJE-20-0562>

Jung, S.L., Baek, J.H., Lee, J.H., Shong, Y.K., Sung, J.Y., Kim, K.S., Lee, D., Kim, J.H., Baek, S.M., Sim, J.S., & Na, D.G. (2018). Efficacy and Safety of Radiofrequency Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study. *Korean Journal of Radiology*, 19(1), 167–174. <https://doi.org/10.3348/kjr.2018.19.1.167>

Kim, J.H., Baek, J.H., Sung, J.Y., et al. (2017). Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: Preliminary results for patients' ineligible for surgery. *Int J Hyperth*, 33(2), 212–9.

- Kim, Y.S., Rhim, H., Tae, K., Park, D.W., & Kim, S.T. (2006). Radiofrequency ablation of benign cold thyroid nodules: Initial clinical experience. *Thyroid*, 16, 361-367.
- Kuo, J.H., & Lee, J.A. (2021). The Adoption of ultrasound-guided radiofrequency ablation of thyroid nodules in the United States. *Ann Surg*, 273, e10-e12.
- Kuo, J.H., McManus, C., & Lee, J.A. (2022). Analyzing the adoption of radiofrequency ablation of thyroid nodules using the diffusion of innovations theory: Understanding where we are in the United States? *Ultrasonography*, 41(1), 25-33. <https://doi.org/10.14366/usg.21117>
- Lee, G.M., You, J.Y., Kim, H.Y., Chai, Y.J., Kim, H.K., Dionigi, G., & Tufano, R.P. (2019). Successful radiofrequency ablation strategies for benign thyroid nodules. *Endocrine*, 64(2), 316–321. <https://doi.org/10.1007/s12020-018-1829-4>
- Lim, H.K., Cho, S.J., Baek, J.H., et al. (2019). US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: Efficacy and safety in a large population. *Korean J Radiol*, 20(12), 1653–61.
- Muhammad, H., Russell, J.O., Santhanam, P., Tehreem, A., & Tufano, R.P. (2021). Current practice of percutaneous ablation technologies for thyroid nodules 2020. *Curr Otorhinolaryngol Rep*. <https://doi.org/10.1007/s40136-020-00323-5>. 2021/01/06
- National Institute for Health and Care Excellence. (2016). Ultrasound-Guided Percutaneous Radiofrequency Ablation for Benign Thyroid Nodules. Retrieved from <https://www.nice.org.uk/guidance/ipg562>
- Orloff, L.A., Noel, J.E., Stack, B.C., et al. (2022). Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society

Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. *Head Neck*, 44(3), 633-660. <https://doi.org/10.1002/hed.26960>

Park, K.W., Shin, J.H., Han, B.K., Ko, E.Y., & Chung, J.H. (2011). Inoperable symptomatic recurrent thyroid cancers: Preliminary result of radiofrequency ablation. *Ann Surg Oncol*, 18(9), 2564–8.

Radzina, M., Cantisani, V., Rauda, M., Nielsen, M.B., Ewertsen, C., D'Ambrosio, F., Prieditis, P. & Sorrenti, S. (2017). Update on the role of ultrasound guided radiofrequency ablation for thyroid nodule treatment. *International Journal of Surgery*, 41(S1), S82-93.
<https://doi.org/10.1016/j.ijssu.2017.02.010>

Wong, K.P. & Lang, B.H.H. (2013). Use of radiofrequency ablation in benign thyroid nodules: a literature review and updates. *International Journal of Endocrinology*, 3, 1-7.
<https://doi.org/10.1155/2013/428363>

Yan, L., Zhang, M., Song, Q., & Luo, Y. (2021). Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma: A Propensity-Matched Cohort Study of 884 Patients. *Thyroid*, 31(11), 1662–1672. <https://doi-org.proxy.lib.ohio-state.edu/10.1089/thy.2021.0100>

Zhang, M., Tufano, R.P., Russell, J.O., Zhang, Y., Qiao, Z., & Luo, Y. (2020). Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: Results of over 5 years' follow-up. *Thyroid*, 30(3), 408–17.